Evidence map›Paper›PMID 37526905›Full record

ArticleDigestive diseases and sciences2023

Nintedanib Alleviates Chronic Pancreatitis by Inhibiting the Activation of Pancreatic Stellate Cells via the JAK/STAT3 and ERK1/2 Pathways.

Chao Han, Li-Juan Wang, Zhi-Qi Dong, Peng-Yuan Wang, Yan-Wei Lv, Dan Wang, Liang-Hao Hu

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Chao Han *Department of Gastroenterology, First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Li-Juan Wang *Department of Gastroenterology, First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Zhi-Qi Dong *Department of Gastroenterology, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, 200434, China.
Peng-Yuan Wang *Department of Gastroenterology, First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Yan-Wei LvDepartment of Gastroenterology, First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Dan WangDepartment of Gastroenterology, First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Liang-Hao HuDepartment of Gastroenterology, First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China. lianghao-hu@smmu.edu.cn.ORCID 0000-0001-7535-7475
Shanghai Institute of Hematology · CNFirst Hospital of Qinhuangdao · CNSecond Military Medical University · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNintedanib (Ninte) has been approved for the treatment of pulmonary fibrosis, and whether it can ameliorate chronic pancreatitis (CP) is unknown.

aimsThis study was conducted to investigate the effect and molecular mechanism of Ninte on pancreatic fibrosis and inflammation in vivo and in vitro.

methodsThe caerulein-induced CP model of murine was applied, and Ninte was orally administered. Pathological changes in pancreas were evaluated using hematoxylin & eosin, Sirius Red, Masson's trichrome, and anti-Ki-67 staining. For in vitro studies, the effects of Ninte on cell viability, apoptosis, and migration of pancreatic stellate cells (PSCs) were determined by CCK-8, flow cytometry, and wound healing assays, respectively. The potential molecular mechanisms of the effects of Ninte on PSCs were analyzed by RNA-Seq and verified at the gene expression and protein activity levels by qRT-PCR and Western Blot.

resultsNinte significantly alleviated the weight loss in mice with caerulein-induced CP and simultaneously attenuated the pancreatic damage, as evidenced by reduced acinar atrophy, collagen deposition, infiltration of inflammatory cells, and inhibited cell proliferation/regeneration. Besides, Ninte markedly suppressed the transcription of fibrogenic and proinflammatory genes in pancreatic tissues. Further in vitro studies showed that Ninte significantly inhibited the transcription and protein expression of genes corresponding to fibrogenesis and proliferation in PSCs. The results of RNA-Seq analysis and subsequent verification assays indicated that Ninte inhibited the activation and proliferation of PSCs via the JAK/STAT3 and ERK1/2 pathways.

conclusionsThese findings indicate that Ninte may be a potential anti-inflammatory and anti-fibrotic therapeutic agent for CP.

Indexed as

MAP Kinase Signaling SystemPancreatitis, ChronicAnimalsCeruletideFibrosisIndolesMicePancreasPancreatic Stellate CellsCeruletideIndolesnintedanibChronic pancreatitisERK1/2JAK/STAT3NintedanibPancreatic fibrosisPancreatic stellate cells

Identifiers

PMID37526905
OpenAlexW4385441737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.